Sign In
Buy RLAY
$15.30
-0.400 (-2.55%)
At Close: Jun 03, 2026
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in June
04:05pm, Wednesday, 27'th May 2026
CAMBRIDGE, Mass., May 27, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies f
Is Relay Therapeutics a Buy After Promising Trial Results?
05:30pm, Friday, 22'nd May 2026
Relay had its initial public offering in 2020. The company's lead therapy is being tested for the treatment of vascular disorders and cancers.
Relay Therapeutics Announces Pricing of Public Offering of Common Stock
08:21pm, Wednesday, 20'th May 2026
CAMBRIDGE, Mass. , May 20, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies
Relay Therapeutics Announces Pricing of Public Offering of Common Stock
08:21pm, Wednesday, 20'th May 2026
CAMBRIDGE, Mass., May 20, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies f
Why Relay Therapeutics Stock Popped on Wednesday
07:01pm, Wednesday, 20'th May 2026
This was aided by a pair of bullish analyst updates. The two pundits raised their price targets and maintained their buy ratings.
Relay Therapeutics: Zovegalisib Is Becoming A Platform In Disguise
04:50am, Wednesday, 20'th May 2026
Relay Therapeutics is undervalued as the market overlooks its potential to build a multi-indication PI3Kα inhibitor franchise beyond breast cancer. Zovegalisib's Breakthrough Therapy designation and
Relay Therapeutics, Inc. (RLAY) Discusses Initial Clinical Data for Zovegalisib in Vascular Anomalies Transcript
11:10pm, Tuesday, 19'th May 2026
Relay Therapeutics, Inc. (RLAY) Discusses Initial Clinical Data for Zovegalisib in Vascular Anomalies Transcript
Relay Therapeutics Announces Proposed Public Offering of Common Stock
04:03pm, Tuesday, 19'th May 2026
CAMBRIDGE, Mass., May 19, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies f
Relay's treatment shown to shrink vascular malformations in mid-stage trial
06:02am, Tuesday, 19'th May 2026
Relay Therapeutics said on Tuesday a mid-stage trial showed its experimental treatment can shrink vascular malformations and improve symptoms in patients with rare vascular disorders.
Promising initial efficacy data with 60% volumetric response rate across doses and 29%* at the lowest tested dose of 100mg twice daily (BID) with all patients ongoing
Relay Therapeutics, Inc. (RLAY) Reports Q1 Loss, Lags Revenue Estimates
07:10pm, Tuesday, 05'th May 2026
Relay Therapeutics, Inc. (RLAY) came out with a quarterly loss of $0.41 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to a loss of $0.46 per share a year ago.
Relay Therapeutics Reports First Quarter 2026 Financial Results and Corporate Updates
04:05pm, Tuesday, 05'th May 2026
FDA Breakthrough Therapy designation granted to zovegalisib for PIK3CA-mutant, HR+/HER2- advanced breast cancer, the Phase 3 ReDiscover-2 trial population in 2L breast cancer
Buy These 3 Clinical-Stage Biotechs Under $30 With Solid Cash Runways
11:07am, Monday, 04'th May 2026
Clinical-stage biotech is one of the few corners of the market where a sub-$30 share price genuinely matters: small-cap oncology names can re-rate violently around a single Phase 3 readout or FDA deci
Relay Therapeutics to Announce First Quarter 2026 Financial Results and Corporate Highlights on May 5, 2026
04:05pm, Wednesday, 29'th Apr 2026
CAMBRIDGE, Mass., April 29, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies
Relay Therapeutics, Inc. (RLAY) Discusses Zovegalisib Triplet Data and First-Line Breast Cancer Strategy Transcript
04:21pm, Monday, 27'th Apr 2026
Relay Therapeutics, Inc. (RLAY) Discusses Zovegalisib Triplet Data and First-Line Breast Cancer Strategy Transcript
